Skip to main
SKIN

SKIN Stock Forecast & Price Target

SKIN Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 25%
Buy 0%
Hold 75%
Sell 0%
Strong Sell 0%

Bulls say

SkinHealth Systems is facing near-term headwinds, including revised revenue guidance for 2026 due to continued device sales weakness, increased competition from knockoffs and scaled down models, and slow stabilization of system sales. However, the company's new CEO is taking proactive measures to address these challenges, including hiring a new head of sales and developing a new Hydrafacial model for launch in 2028. Furthermore, SkinHealth Systems's 4Q results showed strong performance with sales and gross margin beating expectations and growth in consumable sales. Despite macroeconomic risks and competition, the company's strong brand reputation and high-quality products position it well for long-term success in the global skincare and aesthetics market.

Bears say

SkinHealth Systems is facing multiple ongoing legal obligations, including shareholder derivative lawsuits and patent infringement cases, which may continue to negatively impact cash flow. Additionally, one of the company's key patents is set to expire in 2026, and they have been aggressively defending it from counterfeit manufacturers. While they reported strong numbers in their 1Q earnings, their net leverage remains high and they are still facing challenges in certain regions and with device utilization. Furthermore, potential impediments to their stock price target include softening equipment demand and an inability to reduce operating expenses, as well as regulatory risks faced by their products.

SKIN has been analyzed by 4 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 0% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Beauty Health Company (SKIN) Forecast

Analysts have given SKIN a Hold based on their latest research and market trends.

According to 4 analysts, SKIN has a Hold consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.52, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.52, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Beauty Health Company (SKIN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.